Hovione has announced the addition of services for crystal design, particle size reduction to the micro or nano-scale, and amorphous solid dispersions. The company, which provides particle engineering, formulation development, and clinical manufacture to Phase 2 for dry powder inhalers and has its own proprietary DPIs, will by providing more details on the new services at the upcoming AAPS annual meeting.
Hovione Chief Executive Guy Villax said, “We are very pleased to offer our customers these technologies. In response to customers’ needs, Hovione is investing in new technologies, many of them capable of handling highly potent compounds. These will help drive compounds with development challenges from early clinical to market.”
Read the Hovione press release.
